Skip to main content

Peer Review reports

From: Population-based phase II trial of stereotactic ablative radiotherapy (SABR) for up to 5 oligometastases: SABR-5

Original Submission
30 Aug 2018 Submitted Original manuscript
5 Sep 2018 Author responded Author comments - Robert Olson
Resubmission - Version 2
5 Sep 2018 Submitted Manuscript version 2
25 Sep 2018 Author responded Author comments - Robert Olson
Resubmission - Version 3
25 Sep 2018 Submitted Manuscript version 3
Publishing
26 Sep 2018 Editorially accepted
4 Oct 2018 Article published 10.1186/s12885-018-4859-7

You can find further information about peer review here.

Back to article page